Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Clarify Pharma PLC - London-based investor in psychedelics companies - Pretax loss for year ended November 30 narrows to £1.0 million from £1.3 million the previous year. The company makes no revenue for the year. Total assets at November 30 falls by half to £1.5 million from £2.6 million the year prior. The company believes that the sector will develop significantly with the regulatory environment. Executive Director Jonathan Bixby says: ‘We remain confident that our early-stage investment in Beckley Psytech Ltd will generate attractive returns.’
Current stock price: 0.80 pence
12-months change: down 72%
Copyright 2023 Alliance News Ltd. All Rights Reserved.